SERPINC1
ENSG00000117601
Target class
Secreted protein
Chromosome
1
Approved drugs
10
Clinical candidates (approved and in development)
13
- Approved drugs
- 10
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- No
- Target name
- SERPINC1
- Gene name
- Serpin family C member 1
- Gene symbol
- SERPINC1
- Previous gene symbols
- AT3
- Protein name
- Antithrombin-III (ATIII) (Serpin C1)
- ATIII
- MGC22579
- Gene biotype
- Protein coding
- Gene family
- Serpin peptidase inhibitors
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 1,054.38
- Tissue specificity (Gini)
- 0.972
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:462
- Protein interaction confidence
- 0.846865
- Protein interaction partners
- 52
- R-HSA-381426
- R-HSA-8957275
- R-HSA-9769733
- R-HSA-9769735
- R-HSA-9769739
- R-HSA-9769743
- End position
- 173917543
- Start position
- 173903519
- Chromosome
- 1
- Strand
- Reverse
- Secreted, extracellular space.
- Tissue specificity (tau)
- 0.999756
- Expression inequality (Gini)
- 0.972357
Expression in transcripts per million
- Liver
- 1,054.38
- Testis
- 0.99
- Kidney - Cortex
- 0.79
- Whole Blood
- 0.5
- Spleen
- 0.47
Expression in transcripts per million
- Liver1,054.38
- Testis0.99
- Kidney - Cortex0.79
- Whole Blood0.5
- Spleen0.47
- Lung0.43
- Kidney - Medulla0.42
- Artery - Coronary0.36
- Nerve - Tibial0.34
- Artery - Aorta0.33
- Esophagus - Muscularis0.33
- Brain - Cerebellum0.32
- Cervix - Ectocervix0.31
- Cervix - Endocervix0.31
- Pituitary0.31
- Thyroid0.31
- Esophagus - Gastroesophageal Junction0.29
- Fallopian Tube0.29
- Vagina0.27
- Bladder0.27
- Brain - Cerebellar Hemisphere0.27
- Prostate0.27
- Small Intestine - Terminal Ileum0.26
- Esophagus - Mucosa0.25
- Uterus0.25
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0005788
- GO:0005886
- GO:0031012
- GO:0070062
- GO:0072562
- GO:0002020
- GO:0005515
- GO:0042802
Related records
Trials (2,465)
- : Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
- "InDACtion" vs "3+7" Induction in AML
- "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
- "Postoperative Pain Following Laser-Assisted Root Canal Treatment: A Randomized Clinical Trial"
- (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
- 0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment
- 2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy
- 6MW3511 in Patients With Advanced Solid Tumor
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- A 4-weeks Comparative Study of Cosmetic Product Versus Standard Medical Care in Subjects With Seborrheic Dermatitis
- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
- A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries
- A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
- A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
- A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- A Clinical Study of YL205 in Patients With Advanced Solid Tumors
- A Clinical Study on Co-transplantation of Autologous Limbal Stem Cells and Corneal Stromal Stem Cells to Repair Corneal Injury
- A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects
- A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia
Drugs (15)
- Ardeparin sodium Antithrombin-III activator
- Bemiparin sodium Antithrombin-III activator
- Dalteparin sodium Antithrombin-III activator
- Danaparoid sodium Antithrombin-III activator
- Enoxaparin sodium Antithrombin-III activator
- Fitusiran Antithrombin mRNA RNAi inhibitor
- Fondaparinux Antithrombin-III activator
- Fondaparinux sodium Antithrombin-III activator
- Heparin Antithrombin-III activator
- Heparin calcium Antithrombin-III activator
- Heparin sodium Antithrombin-III activator
- Nadroparin calcium Antithrombin-III activator
- Parnaparin sodium Antithrombin-III activator
- Semuloparin sodium Antithrombin-III inhibitor
- Tinzaparin sodium Antithrombin-III activator